Effect of Methylphenidate on Cancer-related Cognitive Impairment
Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Cancer-related cognitive Impairment (CRCI), commonly referred to as "chemo brain" or "brain
fog"-impact severely on the Quality of Life (QoL) of cancer survivors. However, it still
remains underdiagnosed and challenging to treat. One of the treatment options is the use of
psychostimulants such as Methylphenidate (MP), but well-designed clinical trials to test its
efficacy are limited. We will conduct a phase II study with a mixed method design to explore
the preliminary efficacy of MP to improve cognitive function and QoL in breast cancer
patients after treatment with chemotherapy and/or radiotherapy and determine the parameters
needed for designing a phase III study.
Phase:
Phase 2
Details
Lead Sponsor:
Centre Hospitalier Universitaire de Québec, CHU de Québec CHU de Quebec-Universite Laval
Collaborators:
Équipe de Recherche Michel-Sarrazin en Oncologie psychosociale et Soins palliatifs Fondation Hôtel-Dieu de Lévis Purdue Pharma LP